1
|
Holtz A, Van Weyenbergh J, Hong SL, Cuypers L, O'Toole Á, Dudas G, Gerdol M, Potter BI, Ntoumi F, Mapanguy CCM, Vanmechelen B, Wawina-Bokalanga T, Van Holm B, Menezes SM, Soubotko K, Van Pottelbergh G, Wollants E, Vermeersch P, Jacob AS, Maes B, Obbels D, Matheeussen V, Martens G, Gras J, Verhasselt B, Laffut W, Vael C, Goegebuer T, van der Kant R, Rousseau F, Schymkowitz J, Serrano L, Delgado J, Wenseleers T, Bours V, André E, Suchard MA, Rambaut A, Dellicour S, Maes P, Durkin K, Baele G. Emergence of the B.1.214.2 SARS-CoV-2 lineage with an Omicron-like spike insertion and a unique upper airway immune signature. BMC Infect Dis 2024; 24:1139. [PMID: 39390446 PMCID: PMC11468156 DOI: 10.1186/s12879-024-09967-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2024] [Accepted: 09/20/2024] [Indexed: 10/12/2024] Open
Abstract
We investigate the emergence, mutation profile, and dissemination of SARS-CoV-2 lineage B.1.214.2, first identified in Belgium in January 2021. This variant, featuring a 3-amino acid insertion in the spike protein similar to the Omicron variant, was speculated to enhance transmissibility or immune evasion. Initially detected in international travelers, it substantially transmitted in Central Africa, Belgium, Switzerland, and France, peaking in April 2021. Our travel-aware phylogeographic analysis, incorporating travel history, estimated the origin to the Republic of the Congo, with primary European entry through France and Belgium, and multiple smaller introductions during the epidemic. We correlate its spread with human travel patterns and air passenger data. Further, upon reviewing national reports of SARS-CoV-2 outbreaks in Belgian nursing homes, we found this strain caused moderately severe outcomes (8.7% case fatality ratio). A distinct nasopharyngeal immune response was observed in elderly patients, characterized by 80% unique signatures, higher B- and T-cell activation, increased type I IFN signaling, and reduced NK, Th17, and complement system activation, compared to similar outbreaks. This unique immune response may explain the variant's epidemiological behavior and underscores the need for nasal vaccine strategies against emerging variants.
Collapse
Affiliation(s)
- Andrew Holtz
- Lyssavirus Epidemiology and Neuropathology Unit, Institut Pasteur, Université Paris Cité, Paris, France.
| | - Johan Van Weyenbergh
- Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium.
| | - Samuel L Hong
- Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium
| | - Lize Cuypers
- Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium
- Department of Laboratory Medicine, University Hospitals Leuven, National Reference Centre for Respiratory Pathogens, Leuven, Belgium
| | - Áine O'Toole
- Institute of Ecology and Evolution, University of Edinburgh, Edinburgh, UK
| | - Gytis Dudas
- Institute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, Lithuania
| | - Marco Gerdol
- Department of Life Sciences, University of Trieste, Trieste, Italy
| | - Barney I Potter
- Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium
| | - Francine Ntoumi
- Fondation Congolaise Pour La Recherche Médicale, Brazzaville, Republic of Congo
- Institute for Tropical Medicine, University of Tübingen, Tübingen, Germany
| | - Claujens Chastel Mfoutou Mapanguy
- Fondation Congolaise Pour La Recherche Médicale, Brazzaville, Republic of Congo
- Faculty of Sciences and Techniques, University Marien Ngouabi, Brazzaville, Republic of Congo
| | - Bert Vanmechelen
- Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium
| | - Tony Wawina-Bokalanga
- Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium
| | - Bram Van Holm
- Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium
| | - Soraya Maria Menezes
- Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium
| | | | | | - Elke Wollants
- Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium
| | - Pieter Vermeersch
- Department of Laboratory Medicine, University Hospitals Leuven, National Reference Centre for Respiratory Pathogens, Leuven, Belgium
| | - Ann-Sophie Jacob
- Department of Laboratory Medicine, University Hospitals Leuven, National Reference Centre for Respiratory Pathogens, Leuven, Belgium
| | - Brigitte Maes
- Laboratory for Molecular Diagnostics, Jessa Hospital, Hasselt, Belgium
- Hasselt University, Hasselt, Belgium
- Limburg Clinical Research Center, Hasselt, Belgium
| | | | - Veerle Matheeussen
- Department of Laboratory Medicine, Antwerp University Hospital (UZA), Edegem, Belgium
- Laboratory of Medical Biochemistry and Laboratory of Medical Microbiology, University of Antwerp, Wilrijk, Belgium
| | - Geert Martens
- Department of Laboratory Medicine, AZ Delta General Hospital, Roeselare, Belgium
| | - Jérémie Gras
- Institut de Pathologie Et de Génétique, Gosselies, Belgium
| | - Bruno Verhasselt
- Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium
| | - Wim Laffut
- Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium
| | - Carl Vael
- Department of Laboratory Medicine, KLINA General Hospital, Brasschaat, AZ, Belgium
| | | | - Rob van der Kant
- Switch Laboratory, VIB Center for Brain and Disease Research and Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium
- Molecular Medicine, KU Leuven, Leuven, Belgium
| | - Frederic Rousseau
- Switch Laboratory, VIB Center for Brain and Disease Research and Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium
- Molecular Medicine, KU Leuven, Leuven, Belgium
| | - Joost Schymkowitz
- Switch Laboratory, VIB Center for Brain and Disease Research and Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium
- Molecular Medicine, KU Leuven, Leuven, Belgium
| | - Luis Serrano
- Center for Genomic Regulation, Barcelona Institute for Science and Technology, 08003, Barcelona, Spain
- Universitat Pompeu Fabra, 08002, Barcelona, Spain
- Institució Catalana de Recerca I Estudis Avançats, 08010, Barcelona, Spain
| | - Javier Delgado
- Center for Genomic Regulation, Barcelona Institute for Science and Technology, 08003, Barcelona, Spain
| | | | - Vincent Bours
- Department of Medical Genetics, CHU Liege, Liege, Belgium
| | - Emmanuel André
- Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium
| | - Marc A Suchard
- Department of Biostatistics, Fielding School of Public Health, University of California, Los Angeles, CA, USA
| | - Andrew Rambaut
- Institute of Ecology and Evolution, University of Edinburgh, Edinburgh, UK
| | - Simon Dellicour
- Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium
- Université Libre de Bruxelles, Brussels, Belgium
| | - Piet Maes
- Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium
| | - Keith Durkin
- Laboratory of Human Genetics, GIGA Research Institute, Liège, Belgium
| | - Guy Baele
- Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium
| |
Collapse
|
2
|
Sripaew S, Yasharad K, Rahari DS, Feng W, Qian Z, Thanh HN, Li P, Fitriangga A, Purwanto SP, Phyu AN, Xianyu F, Phadungvitvatthana S, Wichaidit W, Kumwichar P, Chongsuvivatwong V. A serological survey of COVID-19 among predominantly aboriginal residents of a tourist island in southern Thailand. Trop Med Health 2024; 52:57. [PMID: 39232844 PMCID: PMC11373474 DOI: 10.1186/s41182-024-00617-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2024] [Accepted: 07/15/2024] [Indexed: 09/06/2024] Open
Abstract
BACKGROUND The current survey describes the seroprevalence, history of coronavirus disease 2019 (COVID-19), and vaccination status among predominantly aboriginal residents on a tourist island in southern Thailand. This information can be translated into COVID-19 vaccination and control plans for this population. METHODS We implemented questionnaire interviews and collected blood samples from 249 residents of Lipe Island, Satun Province, in January 2022. We measured the anti-nucleocapsid protein and anti-spike (anti-S) receptor-binding protein levels of immunoglobulin (Ig) M and IgG. The differences in antibody levels among participants with different histories of vaccination and infection were analyzed using one-way analysis of variance with multiple comparisons. RESULTS During the 2-year pandemic period, no island residents with COVID-19 required hospitalization despite the high prevalence of hypertension (33.3%) and diabetes mellitus (21.7%). Approximately 18.8% of the participants reported a history of COVID-19 diagnosis. In total, 95.1% of the participants had a history of complete vaccination, of which 93.5% were seropositive. The anti-S IgG geometric means (geometric standard deviation) were 3945.8 (2.0), 829.8 (9.7) AU/mL, 789.9 (5.3) AU/mL, and 22.7 (7.1) AU/mL, respectively, in participants with a history of both COVID-19 diagnosis and complete vaccination (group 1), incomplete vaccination and subsequent COVID-19 diagnosis (group 2), complete vaccination but no previous infection (group 3), or neither previous COVID-19 and complete vaccination (group 4). Significant pairwise differences in anti-S IgG levels were found between certain groups (1 vs 3, 1 vs 4, 2 vs 4, and 3 vs 4). CONCLUSIONS The high coverage of vaccination, high levels of population antibody titers, variable antibody levels among completely vaccinated non-infected residents, and high prevalence of non-communicable diseases (NCDs) suggested that the local health systems could control the pandemic. However, continuing surveillance, booster vaccinations, and NCD prevention programs were still required.
Collapse
Affiliation(s)
- Supakorn Sripaew
- Department of Epidemiology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, 90110, Thailand
- Department of Family and Preventive Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand
| | - Kameelah Yasharad
- Office of Disease Prevention and Control Region 12, Songkhla, Thailand
| | - Dzerlina S Rahari
- Department of Epidemiology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, 90110, Thailand
| | - Weiyan Feng
- Department of Epidemiology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, 90110, Thailand
| | - Zhenzhu Qian
- Department of Epidemiology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, 90110, Thailand
| | - Huynh Ngoc Thanh
- Department of Epidemiology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, 90110, Thailand
| | - Pei Li
- Department of Epidemiology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, 90110, Thailand
| | - Agus Fitriangga
- Department of Epidemiology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, 90110, Thailand
| | - Satiti Palupi Purwanto
- Department of Epidemiology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, 90110, Thailand
| | - Aye Nyein Phyu
- Department of Epidemiology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, 90110, Thailand
| | - Fangming Xianyu
- Department of Epidemiology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, 90110, Thailand
| | | | - Wit Wichaidit
- Department of Epidemiology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, 90110, Thailand
| | - Ponlagrit Kumwichar
- Department of Epidemiology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, 90110, Thailand
| | - Virasakdi Chongsuvivatwong
- Department of Epidemiology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, 90110, Thailand.
| |
Collapse
|
3
|
Tramuto F, Marotta C, Stefanelli P, Cernigliaro A, Maida CM, Silenzi A, Angeloni U, Di Naro D, Randazzo G, Guzzetta V, Barone T, Brusaferro S, Severoni S, Rezza G, Vitale F, Mazzucco W, SAMI-Surv Collaboration AlbaDavideAmodioEmanueleCasuccioAlessandraCostantinoClaudioFruscioneSantoImmordinoPalmiraRestivoVincenzoSavatteriAlessandraD’AgostinoNadiaLa MiliaDanielePecoraroLauraPulvirentiClaudioStabileDomenicoCesariCarloZichichiSalvatoreLo PrestiAlessandraGrazianoGiorgioScondottoSalvatoreRealeStefanoScibettaSilviaVitaleFabrizioBarracoChiaraMistrettaGiuseppaPalmeriGiuliaRizzoAntonina PatriziaSparacoAntoninoAgnoneAnnalisaCascioFrancescoDi QuartoDaniela LauraMigliorisiCarmeloD’AmatoStefaniaCucchiaraValentinaGenoveseDarioFrisciaGiuseppeIacolinoGiorgiaSpotoVittorioZappiaMario. SARS-CoV-2 genomic surveillance of migrants arriving to Europe through the Mediterranean routes. J Glob Health 2024; 14:05017. [PMID: 38963881 PMCID: PMC11223754 DOI: 10.7189/jogh.14.05017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/06/2024] Open
Abstract
Background The implementation genomic-based surveillance on emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants in low-income countries, which have inadequate molecular and sequencing capabilities and limited vaccine storage, represents a challenge for public health. To date, there is little evidence on molecular investigations of SARS-CoV-2 variants in areas where they might emerge. We report the findings of an experimental SARS-CoV-2 molecular surveillance programme for migrants, refugees, and asylum seekers arriving to Europe via Italy through the Mediterranean Sea. Methods We descriptively analysed data on migrants collected at entry points in Sicily from February 2021 to May 2022. These entry points are integrated with a network of laboratories fully equipped for molecular analyses, which performed next-generation sequencing and used Nextclade and the Pangolin coronavirus disease 2019 (COVID-19) tools for clade/lineage assignment. Results We obtained 472 full-length SARS-CoV-2 sequences and identified 12 unique clades belonging to 31 different lineages. The delta variant accounted for 43.6% of all genomes, followed by clades 21D (Eta) and 20A (25.4% and 11.4%, respectively). Notably, some of the identified lineages (A.23.1, A.27, and A.29) predicted their introduction into the migration area. The mutation analysis allowed us to identify 617 different amino acid substitutions, 156 amino acid deletions, 7 stop codons, and 6 amino acid insertions. Lastly, we highlighted the geographical distribution patterns of some mutational profiles occurring in the migrants' countries of origin. Conclusions Genome-based molecular surveillance dedicated to migrant populations from low-resource areas may be useful for forecasting new epidemiological scenarios related to SARS-CoV-2 variants or other emerging pathogens, as well as for informing the updating of vaccination strategies.
Collapse
Affiliation(s)
- Fabio Tramuto
- Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties ‘G. D’Alessandro’, University of Palermo, Italy
- Clinical Epidemiology Unit and Regional Reference Laboratory of Western Sicily for the Emergence of COVID-19, University Hospital ‘P. Giaccone’, Palermo, Italy
| | - Claudia Marotta
- General Directorate of Health Prevention, Ministry of Health, Rome, Italy
| | - Paola Stefanelli
- National Institute of Health (Istituto Superiore di Sanità), Rome, Italy
| | | | - Carmelo Massimo Maida
- Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties ‘G. D’Alessandro’, University of Palermo, Italy
- Clinical Epidemiology Unit and Regional Reference Laboratory of Western Sicily for the Emergence of COVID-19, University Hospital ‘P. Giaccone’, Palermo, Italy
| | - Andrea Silenzi
- General Directorate of Health Prevention, Ministry of Health, Rome, Italy
| | - Ulrico Angeloni
- General Directorate of Health Prevention, Ministry of Health, Rome, Italy
| | - Daniela Di Naro
- Clinical Epidemiology Unit and Regional Reference Laboratory of Western Sicily for the Emergence of COVID-19, University Hospital ‘P. Giaccone’, Palermo, Italy
| | - Giulia Randazzo
- Clinical Epidemiology Unit and Regional Reference Laboratory of Western Sicily for the Emergence of COVID-19, University Hospital ‘P. Giaccone’, Palermo, Italy
| | - Valeria Guzzetta
- Clinical Epidemiology Unit and Regional Reference Laboratory of Western Sicily for the Emergence of COVID-19, University Hospital ‘P. Giaccone’, Palermo, Italy
| | - Teresa Barone
- Department of Laboratory Diagnostics, Local Health Unit of Palermo, Palermo, Italy
| | - Silvio Brusaferro
- National Institute of Health (Istituto Superiore di Sanità), Rome, Italy
- University of Udine, Udine, Italy
| | - Santino Severoni
- Health and Migration Programme (PHM), World Health Organization, Geneva, Switzerland
| | - Gianni Rezza
- General Directorate of Health Prevention, Ministry of Health, Rome, Italy
- Vita – Salute San Raffaele University, Milan, Italy
| | - Francesco Vitale
- Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties ‘G. D’Alessandro’, University of Palermo, Italy
- Clinical Epidemiology Unit and Regional Reference Laboratory of Western Sicily for the Emergence of COVID-19, University Hospital ‘P. Giaccone’, Palermo, Italy
| | - Walter Mazzucco
- Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties ‘G. D’Alessandro’, University of Palermo, Italy
- Clinical Epidemiology Unit and Regional Reference Laboratory of Western Sicily for the Emergence of COVID-19, University Hospital ‘P. Giaccone’, Palermo, Italy
- Division of Biostatistics & Epidemiology Research, Cincinnati Children’s Hospital Medical Center, Cincinnati, USA
| | - SAMI-Surv CollaborationAlbaDavideAmodioEmanueleCasuccioAlessandraCostantinoClaudioFruscioneSantoImmordinoPalmiraRestivoVincenzoSavatteriAlessandraD’AgostinoNadiaLa MiliaDanielePecoraroLauraPulvirentiClaudioStabileDomenicoCesariCarloZichichiSalvatoreLo PrestiAlessandraGrazianoGiorgioScondottoSalvatoreRealeStefanoScibettaSilviaVitaleFabrizioBarracoChiaraMistrettaGiuseppaPalmeriGiuliaRizzoAntonina PatriziaSparacoAntoninoAgnoneAnnalisaCascioFrancescoDi QuartoDaniela LauraMigliorisiCarmeloD’AmatoStefaniaCucchiaraValentinaGenoveseDarioFrisciaGiuseppeIacolinoGiorgiaSpotoVittorioZappiaMario
- Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties ‘G. D’Alessandro’, University of Palermo, Italy
- Clinical Epidemiology Unit and Regional Reference Laboratory of Western Sicily for the Emergence of COVID-19, University Hospital ‘P. Giaccone’, Palermo, Italy
- General Directorate of Health Prevention, Ministry of Health, Rome, Italy
- National Institute of Health (Istituto Superiore di Sanità), Rome, Italy
- Regional Health Authority of Sicily, Palermo, Italy
- Department of Laboratory Diagnostics, Local Health Unit of Palermo, Palermo, Italy
- University of Udine, Udine, Italy
- Health and Migration Programme (PHM), World Health Organization, Geneva, Switzerland
- Vita – Salute San Raffaele University, Milan, Italy
- Division of Biostatistics & Epidemiology Research, Cincinnati Children’s Hospital Medical Center, Cincinnati, USA
| |
Collapse
|
4
|
Gallego-García P, Estévez-Gómez N, De Chiara L, Alvariño P, Juiz-González PM, Torres-Beceiro I, Poza M, Vallejo JA, Rumbo-Feal S, Conde-Pérez K, Aja-Macaya P, Ladra S, Moreno-Flores A, Gude-González MJ, Coira A, Aguilera A, Costa-Alcalde JJ, Trastoy R, Barbeito-Castiñeiras G, García-Souto D, Tubio JMC, Trigo-Daporta M, Camacho-Zamora P, Costa JG, González-Domínguez M, Canoura-Fernández L, Glez-Peña D, Pérez-Castro S, Cabrera JJ, Daviña-Núñez C, Godoy-Diz M, Treinta-Álvarez AB, Veiga MI, Sousa JC, Osório NS, Comas I, González-Candelas F, Hong SL, Bollen N, Dellicour S, Baele G, Suchard MA, Lemey P, Agulla A, Bou G, Alonso-García P, Pérez-Del-Molino ML, García-Campello M, Paz-Vidal I, Regueiro B, Posada D. Dispersal history of SARS-CoV-2 in Galicia, Spain. J Med Virol 2024; 96:e29773. [PMID: 38940448 PMCID: PMC11742125 DOI: 10.1002/jmv.29773] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2024] [Revised: 06/18/2024] [Accepted: 06/19/2024] [Indexed: 06/29/2024]
Abstract
The dynamics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission are influenced by a variety of factors, including social restrictions and the emergence of distinct variants. In this study, we delve into the origins and dissemination of the Alpha, Delta, and Omicron-BA.1 variants of concern in Galicia, northwest Spain. For this, we leveraged genomic data collected by the EPICOVIGAL Consortium and from the GISAID database, along with mobility information from other Spanish regions and foreign countries. Our analysis indicates that initial introductions during the Alpha phase were predominantly from other Spanish regions and France. However, as the pandemic progressed, introductions from Portugal and the United States became increasingly significant. The number of detected introductions varied from 96 and 101 for Alpha and Delta to 39 for Omicron-BA.1. Most of these introductions left a low number of descendants (<10), suggesting a limited impact on the evolution of the pandemic in Galicia. Notably, Galicia's major coastal cities emerged as critical hubs for viral transmission, highlighting their role in sustaining and spreading the virus. This research emphasizes the critical role of regional connectivity in the spread of SARS-CoV-2 and offers essential insights for enhancing public health strategies and surveillance measures.
Collapse
Affiliation(s)
- Pilar Gallego-García
- CINBIO, Universidade de Vigo, Vigo, Spain
- Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, Vigo, Spain
| | - Nuria Estévez-Gómez
- CINBIO, Universidade de Vigo, Vigo, Spain
- Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, Vigo, Spain
| | - Loretta De Chiara
- CINBIO, Universidade de Vigo, Vigo, Spain
- Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, Vigo, Spain
- Department of Biochemistry, Genetics, and Immunology, Universidade de Vigo, Vigo, Spain
| | | | - Pedro M Juiz-González
- Servicio de Microbiología del Complejo Hospitalario Universitario de Ferrol, Ferrol, Spain
| | - Isabel Torres-Beceiro
- Servicio de Microbiología del Complejo Hospitalario Universitario de Ferrol, Ferrol, Spain
| | - Margarita Poza
- Microbiology Research Group, Institute of Biomedical Research (INIBIC) - Interdisciplinary Center for Chemistry and Biology (CICA), University of A Coruña (UDC) - CIBER de Enfermedades Infecciosas (CIBERINFEC-ISCIII), Edificio Sur, Hospital Universitario A Coruña, As Xubias, A Coruña, Spain
- Microbiome and Health Group, Faculty of Sciences, University of A Coruña (UDC), A Coruña, Spain
| | - Juan A Vallejo
- Microbiology Research Group, Institute of Biomedical Research (INIBIC) - Interdisciplinary Center for Chemistry and Biology (CICA), University of A Coruña (UDC) - CIBER de Enfermedades Infecciosas (CIBERINFEC-ISCIII), Edificio Sur, Hospital Universitario A Coruña, As Xubias, A Coruña, Spain
| | - Soraya Rumbo-Feal
- Microbiology Research Group, Institute of Biomedical Research (INIBIC) - Interdisciplinary Center for Chemistry and Biology (CICA), University of A Coruña (UDC) - CIBER de Enfermedades Infecciosas (CIBERINFEC-ISCIII), Edificio Sur, Hospital Universitario A Coruña, As Xubias, A Coruña, Spain
| | - Kelly Conde-Pérez
- Microbiology Research Group, Institute of Biomedical Research (INIBIC) - Interdisciplinary Center for Chemistry and Biology (CICA), University of A Coruña (UDC) - CIBER de Enfermedades Infecciosas (CIBERINFEC-ISCIII), Edificio Sur, Hospital Universitario A Coruña, As Xubias, A Coruña, Spain
| | - Pablo Aja-Macaya
- Microbiology Research Group, Institute of Biomedical Research (INIBIC) - Interdisciplinary Center for Chemistry and Biology (CICA), University of A Coruña (UDC) - CIBER de Enfermedades Infecciosas (CIBERINFEC-ISCIII), Edificio Sur, Hospital Universitario A Coruña, As Xubias, A Coruña, Spain
| | - Susana Ladra
- Database Laboratory, Research Center for Information and Communication Technologies (CITIC), University of A Coruña (UDC), A Coruña, Spain
| | | | | | - Amparo Coira
- Department of Microbiology, Complexo Hospitalario Universitario de Santiago de Compostela. SERGAS - Microbiology Research Group, Institute of Biomedical Research (IDIS), Santiago de Compostela, Spain
| | - Antonio Aguilera
- Department of Microbiology, Complexo Hospitalario Universitario de Santiago de Compostela. SERGAS - Microbiology Research Group, Institute of Biomedical Research (IDIS), Santiago de Compostela, Spain
| | - José J Costa-Alcalde
- Department of Microbiology, Complexo Hospitalario Universitario de Santiago de Compostela. SERGAS - Microbiology Research Group, Institute of Biomedical Research (IDIS), Santiago de Compostela, Spain
| | - Rocío Trastoy
- Department of Microbiology, Complexo Hospitalario Universitario de Santiago de Compostela. SERGAS - Microbiology Research Group, Institute of Biomedical Research (IDIS), Santiago de Compostela, Spain
| | - Gema Barbeito-Castiñeiras
- Department of Microbiology, Complexo Hospitalario Universitario de Santiago de Compostela. SERGAS - Microbiology Research Group, Institute of Biomedical Research (IDIS), Santiago de Compostela, Spain
| | - Daniel García-Souto
- CiMUS, Universidade de Santiago de Compostela, Santiago de Compostela, Spain
| | - José M C Tubio
- CiMUS, Universidade de Santiago de Compostela, Santiago de Compostela, Spain
- Department of Zoology, Genetics and Physic Anthropology, Santiago de Compostela, Spain
| | - Matilde Trigo-Daporta
- Clinical Microbiology Unit, Complexo Hospitalario Universitario de Pontevedra, Pontevedra, Spain
| | - Pablo Camacho-Zamora
- Clinical Microbiology Unit, Complexo Hospitalario Universitario de Pontevedra, Pontevedra, Spain
| | - Juan García Costa
- Servicio de Microbiología, Complejo Hospitalario Universitario de Ourense, Ourense, Spain
| | | | - Luis Canoura-Fernández
- Servicio de Microbiología, Complejo Hospitalario Universitario de Ourense, Ourense, Spain
| | - Daniel Glez-Peña
- CINBIO, Universidade de Vigo, Vigo, Spain
- Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, Vigo, Spain
| | - Sonia Pérez-Castro
- Department of Microbiology, Complexo Hospitalario Universitario de Vigo (CHUVI), SERGAS, Vigo, Spain
- Microbiology and Infectology Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, Vigo, Spain
| | - Jorge J Cabrera
- Department of Microbiology, Complexo Hospitalario Universitario de Vigo (CHUVI), SERGAS, Vigo, Spain
- Microbiology and Infectology Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, Vigo, Spain
| | - Carlos Daviña-Núñez
- Microbiology and Infectology Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, Vigo, Spain
| | - Montserrat Godoy-Diz
- Department of Microbiology, Complexo Hospitalario Universitario de Vigo (CHUVI), SERGAS, Vigo, Spain
| | - Ana Belén Treinta-Álvarez
- Department of Microbiology, Complexo Hospitalario Universitario de Vigo (CHUVI), SERGAS, Vigo, Spain
| | - Maria Isabel Veiga
- Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal
- ICVS/3B's-PT Government Associate Laboratory, Guimarães, Portugal
| | - João Carlos Sousa
- Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal
- ICVS/3B's-PT Government Associate Laboratory, Guimarães, Portugal
| | - Nuno S Osório
- Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal
- ICVS/3B's-PT Government Associate Laboratory, Guimarães, Portugal
| | - Iñaki Comas
- Tuberculosis Genomics Unit, BioMedicine Institute of Valencia, Spanish Research Council (CSIC), Valencia, Spain
- CIBER in Epidemiology and Public Health, Madrid, Spain
- Joint Research Unit "Infection and Public Health", FISABIO-University of Valencia, Valencia, Spain
| | - Fernando González-Candelas
- CIBER in Epidemiology and Public Health, Madrid, Spain
- Joint Research Unit "Infection and Public Health", FISABIO-University of Valencia, Valencia, Spain
- Institute for Integrative Systems Biology (I2SysBio), University of Valencia-CSIC, Valencia, Spain
| | - Samuel L Hong
- Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Clinical and Epidemiological Virology, KU Leuven, University of Leuven, Leuven, Belgium
| | - Nena Bollen
- Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Clinical and Epidemiological Virology, KU Leuven, University of Leuven, Leuven, Belgium
| | - Simon Dellicour
- Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Clinical and Epidemiological Virology, KU Leuven, University of Leuven, Leuven, Belgium
- Spatial Epidemiology Lab, Université Libre de Bruxelles, Brussels, Belgium
| | - Guy Baele
- Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Clinical and Epidemiological Virology, KU Leuven, University of Leuven, Leuven, Belgium
| | - Marc A Suchard
- Department of Biostatistics, Fielding School of Public Health, University of California Los Angeles, Los Angeles, California, USA
- Department of Human Genetics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA
- Department of Computational Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA
| | - Philippe Lemey
- Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Clinical and Epidemiological Virology, KU Leuven, University of Leuven, Leuven, Belgium
- Global Virus Network (GVN), Baltimore, Maryland, USA
| | - Andrés Agulla
- Servicio de Microbiología del Complejo Hospitalario Universitario de Ferrol, Ferrol, Spain
| | - Germán Bou
- Microbiology Research Group, Institute of Biomedical Research (INIBIC) - Interdisciplinary Center for Chemistry and Biology (CICA), University of A Coruña (UDC) - CIBER de Enfermedades Infecciosas (CIBERINFEC-ISCIII), Edificio Sur, Hospital Universitario A Coruña, As Xubias, A Coruña, Spain
| | - Pilar Alonso-García
- Servicio de Microbiología, Hospital Universitario Lucus Augusti, Lugo, Spain
| | - María Luisa Pérez-Del-Molino
- Department of Microbiology, Complexo Hospitalario Universitario de Santiago de Compostela. SERGAS - Microbiology Research Group, Institute of Biomedical Research (IDIS), Santiago de Compostela, Spain
| | - Marta García-Campello
- Clinical Microbiology Unit, Complexo Hospitalario Universitario de Pontevedra, Pontevedra, Spain
| | - Isabel Paz-Vidal
- Servicio de Microbiología, Complejo Hospitalario Universitario de Ourense, Ourense, Spain
| | - Benito Regueiro
- Department of Microbiology, Complexo Hospitalario Universitario de Vigo (CHUVI), SERGAS, Vigo, Spain
- Microbiology and Infectology Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, Vigo, Spain
| | - David Posada
- CINBIO, Universidade de Vigo, Vigo, Spain
- Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, Vigo, Spain
- Department of Biochemistry, Genetics, and Immunology, Universidade de Vigo, Vigo, Spain
| |
Collapse
|
5
|
Zhang X, Han D, Wu N. Serum SARS-CoV-2 antibodies in HIV-1-infected patients after inactivated vaccination and SARS-CoV-2 infection. Heliyon 2024; 10:e31731. [PMID: 38828333 PMCID: PMC11140786 DOI: 10.1016/j.heliyon.2024.e31731] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2023] [Revised: 04/19/2024] [Accepted: 05/21/2024] [Indexed: 06/05/2024] Open
Abstract
Objective To monitor post-vaccination antibody production, neutralizing activity, and their dynamics over time in people living with HIV (PLWH). Methods We collected sera from 147 PLWH and 94 healthy controls after vaccination at different time points and examined changes in antibody levels and neutralizing activity using enzyme-linked immunosorbent assay (ELISA) and pseudovirus neutralization assay. Results IgG levels were substantially increased in both PLWH and healthy controls after the booster injection. Antibody levels decreased significantly in both PLWH and controls five months after the booster injection. However, the rate of decrease was not significantly different between the two groups. The generated antibodies demonstrated protective efficacy against the wild-type SARS-CoV-2 strain, but very low protection against the mutant strains. Furthermore, the protection decreased over time. The vaccine was less effective in PLWH with <200/μl CD4 T cells. During the SARS-CoV-2 recovery period, participants had substantially increased serum antibody levels and protective efficacy compared with those who received the booster. Conclusion Both PLWH and controls demonstrated comparable antibody production ability. Vaccines and booster development against SARS-CoV-2 mutant strains should be prioritized in PLWH, especially in those with low CD4 counts.
Collapse
Affiliation(s)
- Xiaodi Zhang
- State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310000, China
- Jinan Microecological Biomedicine Shandong Laboratory, Jinan, Shandong, China
| | - Dating Han
- State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310000, China
- Jinan Microecological Biomedicine Shandong Laboratory, Jinan, Shandong, China
| | - Nanping Wu
- State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310000, China
- Jinan Microecological Biomedicine Shandong Laboratory, Jinan, Shandong, China
| |
Collapse
|
6
|
Götz V, Mathé P, Agarwal P, Hornuss D, Pfau S, Panning M, Prager E, Voll RE, Engelhardt M, Frye BC, Bamberg F, Fuchs J, Müller M, Wagner D, Rieg S. Clinical phenotype and outcome of persistent SARS-CoV-2 replication in immunocompromised hosts: a retrospective observational study in the Omicron era. Infection 2024; 52:923-933. [PMID: 38095753 PMCID: PMC11142974 DOI: 10.1007/s15010-023-02138-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2023] [Accepted: 11/10/2023] [Indexed: 06/02/2024]
Abstract
PURPOSE This study aims to describe clinical, virological and radiological characteristics as well as treatment strategies and outcomes of immunocompromised patients with persistent SARS-CoV-2 replication. METHODS We performed a retrospective cohort study of immunocompromised patients at the University Medical Center Freiburg between 01/2022 and 05/2023. Patients with substantial immunosuppression and persistent SARS-CoV-2 detection (Ct-value < 30 after 14 days) were included. RESULTS 36 patients in our cohort reported mainly fever, dyspnoea or continuous cough. Viral load was significantly higher in concurrent samples taken from the lower respiratory tract (Ct-value = 26) than from the upper respiratory tract (Ct-value = 34). Time of detectable viral RNA after start of antiviral treatment was shorter in patients receiving two antivirals (median 15 days vs. 31 days with one antiviral agent). Short-course antiviral therapy (≤ 5 days) was less efficient in reduction of symptoms and viral load than prolonged therapy > 10 days. In 30% (8/27) of patients with repeated CT scans, we found the emergence of chronic pulmonary changes, which were more frequently in patients with B cell depletion (37%, 7/19) compared to patients with organ transplantation (12%, 2/17). CONCLUSION Ongoing SARS-CoV-2 replication in the lower respiratory tract is a relevant differential diagnosis in patients with severe immunosuppression and continuous cough, fever or dyspnoea even if nasopharyngeal swabs test negative for SARS-CoV-2. Especially in B cell-depleted patients, this may lead to inflammatory or fibrotic-like pulmonary changes, which are partially reversible after inhibition of viral replication. Antiviral therapy seems to be most effective in combination and over a prolonged period of time of > 10 days. TRIAL REGISTRATION NUMBER DRKS 00027299.
Collapse
Affiliation(s)
- Veronika Götz
- Faculty of Medicine, Division of Infectious Diseases, Department of Medicine II, Medical Center, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.
| | - Philipp Mathé
- Faculty of Medicine, Division of Infectious Diseases, Department of Medicine II, Medical Center, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.
| | - Prerana Agarwal
- Faculty of Medicine, Department of Radiology, Medical Center, University of Freiburg, 79106, Freiburg, Germany
| | - Daniel Hornuss
- Faculty of Medicine, Division of Infectious Diseases, Department of Medicine II, Medical Center, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany
| | - Stefanie Pfau
- Faculty of Medicine, Division of Infectious Diseases, Department of Medicine II, Medical Center, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany
| | - Marcus Panning
- Faculty of Medicine, Institute of Virology, Medical Center, University of Freiburg, 79106, Freiburg, Germany
| | - Eric Prager
- Faculty of Medicine, Department of Nephrology, University Medical Center, University of Freiburg, 79106, Freiburg, Germany
| | - Reinhard E Voll
- Faculty of Medicine, Department of Rheumatology and Clinical Immunology, Medical Center, University of Freiburg, 79106, Freiburg, Germany
| | - Monika Engelhardt
- Faculty of Medicine, Department of Internal Medicine I, Hematology, Oncology and Stem Cell Transplantation, University Medical Center, University of Freiburg, 79106, Freiburg, Germany
| | - Björn C Frye
- Faculty of Medicine, Department of Pneumology, Medical Center, University of Freiburg, 79106, Freiburg, Germany
| | - Fabian Bamberg
- Faculty of Medicine, Department of Radiology, Medical Center, University of Freiburg, 79106, Freiburg, Germany
| | - Jonas Fuchs
- Faculty of Medicine, Institute of Virology, Medical Center, University of Freiburg, 79106, Freiburg, Germany
| | - Matthias Müller
- Faculty of Medicine, Division of Infectious Diseases, Department of Medicine II, Medical Center, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany
- Department of Infection Medicine, Medical Service Centre Clotten, 79106, Freiburg, Germany
| | - Dirk Wagner
- Faculty of Medicine, Division of Infectious Diseases, Department of Medicine II, Medical Center, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany
| | - Siegbert Rieg
- Faculty of Medicine, Division of Infectious Diseases, Department of Medicine II, Medical Center, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany
| |
Collapse
|
7
|
Gallego-García P, Estévez-Gómez N, De Chiara L, Alvariño P, Juiz-González PM, Torres-Beceiro I, Poza M, Vallejo JA, Rumbo-Feal S, Conde-Pérez K, Aja-Macaya P, Ladra S, Moreno-Flores A, Gude-González MJ, Coira A, Aguilera A, Costa-Alcalde JJ, Trastoy R, Barbeito-Castiñeiras G, García-Souto D, Tubio JMC, Trigo-Daporta M, Camacho-Zamora P, Costa JG, González-Domínguez M, Canoura-Fernández L, Glez-Peña D, Pérez-Castro S, Cabrera JJ, Daviña-Núñez C, Godoy-Diz M, Treinta-Álvarez AB, Veiga MI, Sousa JC, Osório NS, Comas I, González-Candelas F, Hong SL, Bollen N, Dellicour S, Baele G, Suchard MA, Lemey P, Agulla A, Bou G, Alonso-García P, Pérez-Del-Molino ML, García-Campello M, Paz-Vidal I, Regueiro B, Posada D. Dispersal history of SARS-CoV-2 in Galicia, Spain. MEDRXIV : THE PREPRINT SERVER FOR HEALTH SCIENCES 2024:2024.02.27.24303385. [PMID: 38463998 PMCID: PMC10925372 DOI: 10.1101/2024.02.27.24303385] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/12/2024]
Abstract
The dynamics of SARS-CoV-2 transmission are influenced by a variety of factors, including social restrictions and the emergence of distinct variants. In this study, we delve into the origins and dissemination of the Alpha, Delta, and Omicron variants of concern in Galicia, northwest Spain. For this, we leveraged genomic data collected by the EPICOVIGAL Consortium and from the GISAID database, along with mobility information from other Spanish regions and foreign countries. Our analysis indicates that initial introductions during the Alpha phase were predominantly from other Spanish regions and France. However, as the pandemic progressed, introductions from Portugal and the USA became increasingly significant. Notably, Galicia's major coastal cities emerged as critical hubs for viral transmission, highlighting their role in sustaining and spreading the virus. This research emphasizes the critical role of regional connectivity in the spread of SARS-CoV-2 and offers essential insights for enhancing public health strategies and surveillance measures.
Collapse
Affiliation(s)
- Pilar Gallego-García
- CINBIO, Universidade de Vigo, 36310 Vigo, Spain
- Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO
| | - Nuria Estévez-Gómez
- CINBIO, Universidade de Vigo, 36310 Vigo, Spain
- Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO
| | - Loretta De Chiara
- CINBIO, Universidade de Vigo, 36310 Vigo, Spain
- Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO
- Department of Biochemistry, Genetics, and Immunology, Universidade de Vigo, Vigo 36310, Spain
| | | | - Pedro M Juiz-González
- Servicio de Microbiología del Complejo Hospitalario Universitario de Ferrol, 15405 Ferrol
| | - Isabel Torres-Beceiro
- Servicio de Microbiología del Complejo Hospitalario Universitario de Ferrol, 15405 Ferrol
| | - Margarita Poza
- Microbiology Research Group, Institute of Biomedical Research (INIBIC) - Interdisciplinary Center for Chemistry and Biology (CICA) - University of A Coruña (UDC) - CIBER de Enfermedades Infecciosas (CIBERINFEC-ISCIII), Madrid. Servicio de Microbiología, 3° planta, Edificio Sur, Hospital Universitario A Coruña, As Xubias, 15006, A Coruña, Spain
- Microbiome and Health Group, Faculty of Sciences, University of A Coruña (UDC). Campus da Zapateira, 15008, A Coruña, Spain
| | - Juan A Vallejo
- Microbiology Research Group, Institute of Biomedical Research (INIBIC) - Interdisciplinary Center for Chemistry and Biology (CICA) - University of A Coruña (UDC) - CIBER de Enfermedades Infecciosas (CIBERINFEC-ISCIII), Madrid. Servicio de Microbiología, 3° planta, Edificio Sur, Hospital Universitario A Coruña, As Xubias, 15006, A Coruña, Spain
| | - Soraya Rumbo-Feal
- Microbiology Research Group, Institute of Biomedical Research (INIBIC) - Interdisciplinary Center for Chemistry and Biology (CICA) - University of A Coruña (UDC) - CIBER de Enfermedades Infecciosas (CIBERINFEC-ISCIII), Madrid. Servicio de Microbiología, 3° planta, Edificio Sur, Hospital Universitario A Coruña, As Xubias, 15006, A Coruña, Spain
| | - Kelly Conde-Pérez
- Microbiology Research Group, Institute of Biomedical Research (INIBIC) - Interdisciplinary Center for Chemistry and Biology (CICA) - University of A Coruña (UDC) - CIBER de Enfermedades Infecciosas (CIBERINFEC-ISCIII), Madrid. Servicio de Microbiología, 3° planta, Edificio Sur, Hospital Universitario A Coruña, As Xubias, 15006, A Coruña, Spain
| | - Pablo Aja-Macaya
- Microbiology Research Group, Institute of Biomedical Research (INIBIC) - Interdisciplinary Center for Chemistry and Biology (CICA) - University of A Coruña (UDC) - CIBER de Enfermedades Infecciosas (CIBERINFEC-ISCIII), Madrid. Servicio de Microbiología, 3° planta, Edificio Sur, Hospital Universitario A Coruña, As Xubias, 15006, A Coruña, Spain
| | - Susana Ladra
- Database Laboratory, Research Center for Information and Communication Technologies (CITIC), University of A Coruña (UDC), Campus de Elviña, 15071 A Coruña, Spain
| | | | | | - Amparo Coira
- Microbiology Department, Complexo Hospitalario Universitario de Santiago de Compostela. SERGAS - Microbiology Research Group, Institute of Biomedical Research (IDIS) - Santiago de Compostela 15706, Spain
| | - Antonio Aguilera
- Microbiology Department, Complexo Hospitalario Universitario de Santiago de Compostela. SERGAS - Microbiology Research Group, Institute of Biomedical Research (IDIS) - Santiago de Compostela 15706, Spain
| | - José J Costa-Alcalde
- Microbiology Department, Complexo Hospitalario Universitario de Santiago de Compostela. SERGAS - Microbiology Research Group, Institute of Biomedical Research (IDIS) - Santiago de Compostela 15706, Spain
| | - Rocío Trastoy
- Microbiology Department, Complexo Hospitalario Universitario de Santiago de Compostela. SERGAS - Microbiology Research Group, Institute of Biomedical Research (IDIS) - Santiago de Compostela 15706, Spain
| | - Gema Barbeito-Castiñeiras
- Microbiology Department, Complexo Hospitalario Universitario de Santiago de Compostela. SERGAS - Microbiology Research Group, Institute of Biomedical Research (IDIS) - Santiago de Compostela 15706, Spain
| | - Daniel García-Souto
- CiMUS, Universidade de Santiago de Compostela, 15782, Santiago de Compostela, Spain. - Department of Zoology, Genetics and Physic Anthropology, 15782, Santiago de Compostela, Spain
| | - José M C Tubio
- CiMUS, Universidade de Santiago de Compostela, 15782, Santiago de Compostela, Spain. - Department of Zoology, Genetics and Physic Anthropology, 15782, Santiago de Compostela, Spain
| | - Matilde Trigo-Daporta
- Clinical Microbiology Unit, Complexo Hospitalario Universitario de Pontevedra, Pontevedra, Spain
| | - Pablo Camacho-Zamora
- Clinical Microbiology Unit, Complexo Hospitalario Universitario de Pontevedra, Pontevedra, Spain
| | - Juan García Costa
- Servicio de Microbiología. Complejo Hospitalario Universitario de Ourense, 32005, Ourense, Spain
| | - María González-Domínguez
- Servicio de Microbiología. Complejo Hospitalario Universitario de Ourense, 32005, Ourense, Spain
| | - Luis Canoura-Fernández
- Servicio de Microbiología. Complejo Hospitalario Universitario de Ourense, 32005, Ourense, Spain
| | - Daniel Glez-Peña
- CINBIO, Universidade de Vigo, 36310 Vigo, Spain
- Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO
| | - Sonia Pérez-Castro
- Microbiology Department, Complexo Hospitalario Universitario de Vigo (CHUVI), SERGAS, Vigo 36213, Spain
- Microbiology and Infectology Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, Vigo, Spain
| | - Jorge J Cabrera
- Microbiology Department, Complexo Hospitalario Universitario de Vigo (CHUVI), SERGAS, Vigo 36213, Spain
- Microbiology and Infectology Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, Vigo, Spain
| | - Carlos Daviña-Núñez
- Microbiology and Infectology Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, Vigo, Spain
| | - Montserrat Godoy-Diz
- Microbiology Department, Complexo Hospitalario Universitario de Vigo (CHUVI), SERGAS, Vigo 36213, Spain
| | - Ana Belén Treinta-Álvarez
- Microbiology Department, Complexo Hospitalario Universitario de Vigo (CHUVI), SERGAS, Vigo 36213, Spain
| | - Maria Isabel Veiga
- Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus Gualtar, 4710-057 Braga, Portugal - ICVS/3B's-PT Government Associate Laboratory, 4806-909, Guimarães/ Braga, Portugal
| | - João Carlos Sousa
- Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus Gualtar, 4710-057 Braga, Portugal - ICVS/3B's-PT Government Associate Laboratory, 4806-909, Guimarães/ Braga, Portugal
| | - Nuno S Osório
- Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus Gualtar, 4710-057 Braga, Portugal - ICVS/3B's-PT Government Associate Laboratory, 4806-909, Guimarães/ Braga, Portugal
| | - Iñaki Comas
- Tuberculosis Genomics Unit, Biomedicine Institute of Valencia, Spanish Research Council (CSIC), Valencia, Spain
- CIBER in Epidemiology and Public Health, Spain; Joint Research Unit "Infection and Public Health" FISABIO-University of Valencia, Valencia, Spain
| | - Fernando González-Candelas
- CIBER in Epidemiology and Public Health, Spain; Joint Research Unit "Infection and Public Health" FISABIO-University of Valencia, Valencia, Spain
- Institute for Integrative Systems Biology (I2SysBio), University of Valencia-CSIC, Valencia, Spain
| | - Samuel L Hong
- Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Clinical and Epidemiological Virology, KU Leuven - University of Leuven, 3000 Leuven, Belgium
| | - Nena Bollen
- Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Clinical and Epidemiological Virology, KU Leuven - University of Leuven, 3000 Leuven, Belgium
| | - Simon Dellicour
- Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Clinical and Epidemiological Virology, KU Leuven - University of Leuven, 3000 Leuven, Belgium
- Spatial Epidemiology Lab, Université Libre de Bruxelles, 1000 Brussels, Belgium
| | - Guy Baele
- Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Clinical and Epidemiological Virology, KU Leuven - University of Leuven, 3000 Leuven, Belgium
| | - Marc A Suchard
- Department of Biostatistics, Fielding School of Public Health, University of California Los Angeles, Los Angeles, CA 90095, USA - Department of Human Genetics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA - Department of Computational Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
| | - Philippe Lemey
- Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Clinical and Epidemiological Virology, KU Leuven - University of Leuven, 3000 Leuven, Belgium
- Global Virus Network (GVN), Baltimore, MD 21201, USA
| | - Andrés Agulla
- Servicio de Microbiología del Complejo Hospitalario Universitario de Ferrol, 15405 Ferrol
| | - Germán Bou
- Microbiology Research Group, Institute of Biomedical Research (INIBIC) - Interdisciplinary Center for Chemistry and Biology (CICA) - University of A Coruña (UDC) - CIBER de Enfermedades Infecciosas (CIBERINFEC-ISCIII), Madrid. Servicio de Microbiología, 3° planta, Edificio Sur, Hospital Universitario A Coruña, As Xubias, 15006, A Coruña, Spain
| | - Pilar Alonso-García
- Servicio de Microbiología, Hospital Universitario Lucus Augusti, Lugo, Spain
| | - María Luisa Pérez-Del-Molino
- Microbiology Department, Complexo Hospitalario Universitario de Santiago de Compostela. SERGAS - Microbiology Research Group, Institute of Biomedical Research (IDIS) - Santiago de Compostela 15706, Spain
| | - Marta García-Campello
- Clinical Microbiology Unit, Complexo Hospitalario Universitario de Pontevedra, Pontevedra, Spain
| | - Isabel Paz-Vidal
- Servicio de Microbiología. Complejo Hospitalario Universitario de Ourense, 32005, Ourense, Spain
| | - Benito Regueiro
- Microbiology Department, Complexo Hospitalario Universitario de Vigo (CHUVI), SERGAS, Vigo 36213, Spain
- Microbiology and Infectology Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, Vigo, Spain
| | - David Posada
- CINBIO, Universidade de Vigo, 36310 Vigo, Spain
- Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO
- Department of Biochemistry, Genetics, and Immunology, Universidade de Vigo, Vigo 36310, Spain
| |
Collapse
|
8
|
Le K, Kannappan S, Kim T, Lee JH, Lee HR, Kim KK. Structural understanding of SARS-CoV-2 virus entry to host cells. Front Mol Biosci 2023; 10:1288686. [PMID: 38033388 PMCID: PMC10683510 DOI: 10.3389/fmolb.2023.1288686] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2023] [Accepted: 10/16/2023] [Indexed: 12/02/2023] Open
Abstract
Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a major global health concern associated with millions of fatalities worldwide. Mutant variants of the virus have further exacerbated COVID-19 mortality and infection rates, emphasizing the urgent need for effective preventive strategies. Understanding the viral infection mechanism is crucial for developing therapeutics and vaccines. The entry of SARS-CoV-2 into host cells is a key step in the infection pathway and has been targeted for drug development. Despite numerous reviews of COVID-19 and the virus, there is a lack of comprehensive reviews focusing on the structural aspects of viral entry. In this review, we analyze structural changes in Spike proteins during the entry process, dividing the entry process into prebinding, receptor binding, proteolytic cleavage, and membrane fusion steps. By understanding the atomic-scale details of viral entry, we can better target the entry step for intervention strategies. We also examine the impacts of mutations in Spike proteins, including the Omicron variant, on viral entry. Structural information provides insights into the effects of mutations and can guide the development of therapeutics and vaccines. Finally, we discuss available structure-based approaches for the development of therapeutics and vaccines. Overall, this review provides a detailed analysis of the structural aspects of SARS-CoV-2 viral entry, highlighting its significance in the development of therapeutics and vaccines against COVID-19. Therefore, our review emphasizes the importance of structural information in combating SARS-CoV-2 infection.
Collapse
Affiliation(s)
- Kim Le
- Department of Precision Medicine, Sungkyunkwan University School of Medicine, Institute of Antibacterial Resistance Research and Therapeutics, Sungkyunkwan University, Suwon, Republic of Korea
| | - Shrute Kannappan
- Department of Precision Medicine, Sungkyunkwan University School of Medicine, Institute of Antibacterial Resistance Research and Therapeutics, Sungkyunkwan University, Suwon, Republic of Korea
- Research Center for Advanced Materials Technology Core Research Institute, Suwon, Republic of Korea
| | - Truc Kim
- Department of Precision Medicine, Sungkyunkwan University School of Medicine, Institute of Antibacterial Resistance Research and Therapeutics, Sungkyunkwan University, Suwon, Republic of Korea
| | - Jung Heon Lee
- Research Center for Advanced Materials Technology Core Research Institute, Suwon, Republic of Korea
- School of Advanced Materials and Science Engineering, Sungkyunkwan University, Suwon, Republic of Korea
| | - Hye-Ra Lee
- Department of Biotechnology and Bioinformatics, College of Science and Technology, Korea University, Sejong, Republic of Korea
| | - Kyeong Kyu Kim
- Department of Precision Medicine, Sungkyunkwan University School of Medicine, Institute of Antibacterial Resistance Research and Therapeutics, Sungkyunkwan University, Suwon, Republic of Korea
| |
Collapse
|
9
|
Anoh EA, Wayoro O, Monemo P, Belarbi E, Sachse A, Wilkinson E, San JE, Leendertz FH, Diané B, Calvignac-Spencer S, Akoua-Koffi C, Schubert G. Subregional origins of emerging SARS-CoV-2 variants during the second pandemic wave in Côte d'Ivoire. Virus Genes 2023; 59:370-376. [PMID: 36932280 PMCID: PMC10023306 DOI: 10.1007/s11262-023-01984-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2023] [Accepted: 02/22/2023] [Indexed: 03/19/2023]
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with increased transmissibility, virulence and immune escape abilities have heavily altered the COVID-19 pandemic's course. Deciphering local and global transmission patterns of those variants is thus key in building a profound understanding of the virus' spread around the globe. In the present study, we investigate SARS-CoV-2 variant epidemiology in Côte d'Ivoire, Western sub-Saharan Africa. We therefore generated 234 full SARS-CoV-2 genomes stemming from Central and Northern Côte d'Ivoire. Covering the first and second pandemic wave the country had been facing, we identified 20 viral lineages and showed that in Côte d'Ivoire the second pandemic wave in 2021 was driven by the spread of the Alpha (B.1.1.7) and Eta (B.1.525) variant. Our analyses are consistent with a limited number of international introductions of Alpha and Eta into Côte d'Ivoire, and those introduction events mostly stemmed from within the West African subregion. This suggests that subregional travel to Côte d'Ivoire had more impact on local pandemic waves than direct intercontinental travel.
Collapse
Affiliation(s)
- Etilé A Anoh
- Centre Hospitalier et Universitaire de Bouaké, Bouaké, Côte d'Ivoire
| | - Oby Wayoro
- Centre Hospitalier et Universitaire de Bouaké, Bouaké, Côte d'Ivoire
| | - Pacôme Monemo
- Centre Hospitalier et Universitaire de Bouaké, Bouaké, Côte d'Ivoire
- Université Alassane Ouattara de Bouaké, Bouaké, Côte d'Ivoire
| | - Essia Belarbi
- Robert Koch Institute, Nordufer 20, 13353, Berlin, Germany
| | - Andreas Sachse
- Robert Koch Institute, Nordufer 20, 13353, Berlin, Germany
- Helmholtz Institute for One Health, Greifswald, Germany
| | - Eduan Wilkinson
- KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa
- Centre for Epidemic Response and Innovation (CERI), School for Data Science and Computational Thinking, Stellenbosch University, Stellenbosch, South Africa
| | - James E San
- KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa
| | - Fabian H Leendertz
- Robert Koch Institute, Nordufer 20, 13353, Berlin, Germany
- Helmholtz Institute for One Health, Greifswald, Germany
| | - Bamourou Diané
- Centre Hospitalier et Universitaire de Bouaké, Bouaké, Côte d'Ivoire
| | | | - Chantal Akoua-Koffi
- Centre Hospitalier et Universitaire de Bouaké, Bouaké, Côte d'Ivoire
- Université Alassane Ouattara de Bouaké, Bouaké, Côte d'Ivoire
| | - Grit Schubert
- Robert Koch Institute, Nordufer 20, 13353, Berlin, Germany.
| |
Collapse
|
10
|
Jaki L, Weigang S, Kern L, Kramme S, Wrobel AG, Grawitz AB, Nawrath P, Martin SR, Dähne T, Beer J, Disch M, Kolb P, Gutbrod L, Reuter S, Warnatz K, Schwemmle M, Gamblin SJ, Neumann-Haefelin E, Schnepf D, Welte T, Kochs G, Huzly D, Panning M, Fuchs J. Total escape of SARS-CoV-2 from dual monoclonal antibody therapy in an immunocompromised patient. Nat Commun 2023; 14:1999. [PMID: 37037847 PMCID: PMC10085998 DOI: 10.1038/s41467-023-37591-w] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2022] [Accepted: 03/22/2023] [Indexed: 04/12/2023] Open
Abstract
Monoclonal antibodies (mAbs) directed against the spike of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are effective therapeutic options to combat infections in high-risk patients. Here, we report the adaptation of SARS-CoV-2 to the mAb cocktail REGN-COV in a kidney transplant patient with hypogammaglobulinemia. Following mAb treatment, the patient did not clear the infection. During viral persistence, SARS-CoV-2 acquired three novel spike mutations. Neutralization and mouse protection analyses demonstrate a complete viral escape from REGN-COV at the expense of ACE-2 binding. Final clearance of the virus occurred upon reduction of the immunosuppressive regimen and total IgG substitution. Serology suggests that the development of highly neutralizing IgM rather than IgG substitution aids clearance. Our findings emphasise that selection pressure by mAbs on SARS-CoV-2 can lead to development of escape variants in immunocompromised patients. Thus, modification of immunosuppressive therapy, if possible, might be preferable to control and clearance of the viral infection.
Collapse
Affiliation(s)
- Lena Jaki
- Institute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Sebastian Weigang
- Institute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Lisa Kern
- Institute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Stefanie Kramme
- Institute for Infection Prevention and Hospital Epidemiology, Freiburg University Medical Center, University of Freiburg, Freiburg, Germany
| | - Antoni G Wrobel
- The Structural Biology of Disease Processes Laboratory, The Francis Crick Institute, London, UK
| | - Andrea B Grawitz
- Institute for Clinical Chemistry and Laboratory Medicine, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Philipp Nawrath
- The Structural Biology of Disease Processes Laboratory, The Francis Crick Institute, London, UK
| | - Stephen R Martin
- The Structural Biology of Disease Processes Laboratory, The Francis Crick Institute, London, UK
| | - Theo Dähne
- Institute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Julius Beer
- Institute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Miriam Disch
- Institute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Philipp Kolb
- Institute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Lisa Gutbrod
- Institute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Sandra Reuter
- Institute for Infection Prevention and Hospital Epidemiology, Freiburg University Medical Center, University of Freiburg, Freiburg, Germany
| | - Klaus Warnatz
- Department of Rheumatology and Clinical Immunology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany
- Center for Chronic Immunodeficiency (CCI), Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Martin Schwemmle
- Institute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Steven J Gamblin
- The Structural Biology of Disease Processes Laboratory, The Francis Crick Institute, London, UK
| | - Elke Neumann-Haefelin
- Renal Division, Department of Medicine, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Daniel Schnepf
- Institute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Thomas Welte
- Renal Division, Department of Medicine, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany
- Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
| | - Georg Kochs
- Institute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Daniela Huzly
- Institute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Marcus Panning
- Institute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
| | - Jonas Fuchs
- Institute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
| |
Collapse
|
11
|
Layan M, Müller NF, Dellicour S, De Maio N, Bourhy H, Cauchemez S, Baele G. Impact and mitigation of sampling bias to determine viral spread: Evaluating discrete phylogeography through CTMC modeling and structured coalescent model approximations. Virus Evol 2023; 9:vead010. [PMID: 36860641 PMCID: PMC9969415 DOI: 10.1093/ve/vead010] [Citation(s) in RCA: 20] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2022] [Revised: 01/06/2023] [Accepted: 02/02/2023] [Indexed: 02/08/2023] Open
Abstract
Bayesian phylogeographic inference is a powerful tool in molecular epidemiological studies, which enables reconstruction of the origin and subsequent geographic spread of pathogens. Such inference is, however, potentially affected by geographic sampling bias. Here, we investigated the impact of sampling bias on the spatiotemporal reconstruction of viral epidemics using Bayesian discrete phylogeographic models and explored different operational strategies to mitigate this impact. We considered the continuous-time Markov chain (CTMC) model and two structured coalescent approximations (Bayesian structured coalescent approximation [BASTA] and marginal approximation of the structured coalescent [MASCOT]). For each approach, we compared the estimated and simulated spatiotemporal histories in biased and unbiased conditions based on the simulated epidemics of rabies virus (RABV) in dogs in Morocco. While the reconstructed spatiotemporal histories were impacted by sampling bias for the three approaches, BASTA and MASCOT reconstructions were also biased when employing unbiased samples. Increasing the number of analyzed genomes led to more robust estimates at low sampling bias for the CTMC model. Alternative sampling strategies that maximize the spatiotemporal coverage greatly improved the inference at intermediate sampling bias for the CTMC model, and to a lesser extent, for BASTA and MASCOT. In contrast, allowing for time-varying population sizes in MASCOT resulted in robust inference. We further applied these approaches to two empirical datasets: a RABV dataset from the Philippines and a SARS-CoV-2 dataset describing its early spread across the world. In conclusion, sampling biases are ubiquitous in phylogeographic analyses but may be accommodated by increasing the sample size, balancing spatial and temporal composition in the samples, and informing structured coalescent models with reliable case count data.
Collapse
Affiliation(s)
| | | | | | | | - Hervé Bourhy
- Lyssavirus Epidemiology and Neuropathology Unit, Institut Pasteur, Université Paris Cité, 25-28 rue du Docteur Roux, Paris 75014, France,WHO Collaborating Centre for Reference and Research on Rabies, Institut Pasteur, Université Paris Cité, 28 rue du Docteur Roux, Paris 75724, France
| | | | | |
Collapse
|
12
|
Boer JC, Pan Q, Holien JK, Nguyen TB, Ascher DB, Plebanski M. A bias of Asparagine to Lysine mutations in SARS-CoV-2 outside the receptor binding domain affects protein flexibility. Front Immunol 2022; 13:954435. [PMID: 36569921 PMCID: PMC9788125 DOI: 10.3389/fimmu.2022.954435] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2022] [Accepted: 11/14/2022] [Indexed: 12/14/2022] Open
Abstract
Introduction COVID-19 pandemic has been threatening public health and economic development worldwide for over two years. Compared with the original SARS-CoV-2 strain reported in 2019, the Omicron variant (B.1.1.529.1) is more transmissible. This variant has 34 mutations in its Spike protein, 15 of which are present in the Receptor Binding Domain (RBD), facilitating viral internalization via binding to the angiotensin-converting enzyme 2 (ACE2) receptor on endothelial cells as well as promoting increased immune evasion capacity. Methods Herein we compared SARS-CoV-2 proteins (including ORF3a, ORF7, ORF8, Nucleoprotein (N), membrane protein (M) and Spike (S) proteins) from multiple ancestral strains. We included the currently designated original Variant of Concern (VOC) Omicron, its subsequent emerged variants BA.1, BA2, BA3, BA.4, BA.5, the two currently emerging variants BQ.1 and BBX.1, and compared these with the previously circulating VOCs Alpha, Beta, Gamma, and Delta, to better understand the nature and potential impact of Omicron specific mutations. Results Only in Omicron and its subvariants, a bias toward an Asparagine to Lysine (N to K) mutation was evident within the Spike protein, including regions outside the RBD domain, while none of the regions outside the Spike protein domain were characterized by this mutational bias. Computational structural analysis revealed that three of these specific mutations located in the central core region, contribute to a preference for the alteration of conformations of the Spike protein. Several mutations in the RBD which have circulated across most Omicron subvariants were also analysed, and these showed more potential for immune escape. Conclusion This study emphasizes the importance of understanding how specific N to K mutations outside of the RBD region affect SARS-CoV-2 conformational changes and the need for neutralizing antibodies for Omicron to target a subset of conformationally dependent B cell epitopes.
Collapse
Affiliation(s)
- Jennifer C. Boer
- School of Health and Biomedical Science, Royal Melbourne Institute of Technology, Melbourne, VIC, Australia
| | - Qisheng Pan
- School of Chemistry and Molecular Biosciences, University of Queensland, Brisbane, QLD, Australia,Computational Biology and Clinical Informatics, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia
| | - Jessica K. Holien
- School of Science, Royal Melbourne Institute of Technology (RMIT) University, Melbourne, VIC, Australia
| | - Thanh-Binh Nguyen
- School of Chemistry and Molecular Biosciences, University of Queensland, Brisbane, QLD, Australia,Computational Biology and Clinical Informatics, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia
| | - David B. Ascher
- School of Chemistry and Molecular Biosciences, University of Queensland, Brisbane, QLD, Australia,Computational Biology and Clinical Informatics, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia
| | - Magdalena Plebanski
- School of Health and Biomedical Science, Royal Melbourne Institute of Technology, Melbourne, VIC, Australia,*Correspondence: Magdalena Plebanski,
| |
Collapse
|
13
|
Beer J, Crotta S, Breithaupt A, Ohnemus A, Becker J, Sachs B, Kern L, Llorian M, Ebert N, Labroussaa F, Nhu Thao TT, Trueeb BS, Jores J, Thiel V, Beer M, Fuchs J, Kochs G, Wack A, Schwemmle M, Schnepf D. Impaired immune response drives age-dependent severity of COVID-19. J Exp Med 2022; 219:e20220621. [PMID: 36129445 PMCID: PMC9499827 DOI: 10.1084/jem.20220621] [Citation(s) in RCA: 35] [Impact Index Per Article: 11.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2022] [Revised: 08/05/2022] [Accepted: 09/01/2022] [Indexed: 11/09/2022] Open
Abstract
Severity of COVID-19 shows an extraordinary correlation with increasing age. We generated a mouse model for severe COVID-19 and show that the age-dependent disease severity is caused by the disruption of a timely and well-coordinated innate and adaptive immune response due to impaired interferon (IFN) immunity. Aggravated disease in aged mice was characterized by a diminished IFN-γ response and excessive virus replication. Accordingly, adult IFN-γ receptor-deficient mice phenocopied the age-related disease severity, and supplementation of IFN-γ reversed the increased disease susceptibility of aged mice. Further, we show that therapeutic treatment with IFN-λ in adults and a combinatorial treatment with IFN-γ and IFN-λ in aged Ifnar1-/- mice was highly efficient in protecting against severe disease. Our findings provide an explanation for the age-dependent disease severity and clarify the nonredundant antiviral functions of type I, II, and III IFNs during SARS-CoV-2 infection in an age-dependent manner. Our data suggest that highly vulnerable individuals could benefit from immunotherapy combining IFN-γ and IFN-λ.
Collapse
Affiliation(s)
- Julius Beer
- Institute of Virology, Medical Center University of Freiburg, Freiburg, Germany
| | - Stefania Crotta
- Immunoregulation Laboratory, The Francis Crick Institute, London, UK
| | - Angele Breithaupt
- Department of Experimental Animal Facilities and Biorisk Management, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany
| | - Annette Ohnemus
- Institute of Virology, Medical Center University of Freiburg, Freiburg, Germany
| | - Jan Becker
- Institute of Virology, Medical Center University of Freiburg, Freiburg, Germany
| | - Benedikt Sachs
- Institute of Virology, Medical Center University of Freiburg, Freiburg, Germany
| | - Lisa Kern
- Institute of Virology, Medical Center University of Freiburg, Freiburg, Germany
| | - Miriam Llorian
- Bioinformatics and Biostatistics, The Francis Crick Institute, London, UK
| | - Nadine Ebert
- Institute of Virology and Immunology, Bern, Switzerland
- Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland
| | - Fabien Labroussaa
- Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland
- Institute of Veterinary Bacteriology, Vetsuisse Faculty, University of Bern, Bern, Switzerland
| | - Tran Thi Nhu Thao
- Institute of Virology and Immunology, Bern, Switzerland
- Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland
- Graduate School for Biomedical Science, University of Bern, Bern, Switzerland
| | - Bettina Salome Trueeb
- Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland
- Institute of Veterinary Bacteriology, Vetsuisse Faculty, University of Bern, Bern, Switzerland
| | - Joerg Jores
- Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland
- Institute of Veterinary Bacteriology, Vetsuisse Faculty, University of Bern, Bern, Switzerland
| | - Volker Thiel
- Institute of Virology and Immunology, Bern, Switzerland
- Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland
- Multidisciplinary Center for Infectious Diseases, University of Bern, Switzerland
| | - Martin Beer
- Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany
| | - Jonas Fuchs
- Institute of Virology, Medical Center University of Freiburg, Freiburg, Germany
| | - Georg Kochs
- Institute of Virology, Medical Center University of Freiburg, Freiburg, Germany
| | - Andreas Wack
- Immunoregulation Laboratory, The Francis Crick Institute, London, UK
| | - Martin Schwemmle
- Institute of Virology, Medical Center University of Freiburg, Freiburg, Germany
- Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Daniel Schnepf
- Institute of Virology, Medical Center University of Freiburg, Freiburg, Germany
| |
Collapse
|
14
|
Taddeo A, Veiga IB, Devisme C, Boss R, Plattet P, Weigang S, Kochs G, Thiel V, Benarafa C, Zimmer G. Optimized intramuscular immunization with VSV-vectored spike protein triggers a superior immune response to SARS-CoV-2. NPJ Vaccines 2022; 7:82. [PMID: 35879345 PMCID: PMC9309237 DOI: 10.1038/s41541-022-00508-7] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2021] [Accepted: 06/21/2022] [Indexed: 11/09/2022] Open
Abstract
Immunization with vesicular stomatitis virus (VSV)-vectored COVID-19 vaccine candidates expressing the SARS-CoV-2 spike protein in place of the VSV glycoprotein relies implicitly on expression of the ACE2 receptor at the muscular injection site. Here, we report that such a viral vector vaccine did not induce protective immunity following intramuscular immunization of K18-hACE2 transgenic mice. However, when the viral vector was trans-complemented with the VSV glycoprotein, intramuscular immunization resulted in high titers of spike-specific neutralizing antibodies. The vaccinated animals were fully protected following infection with a lethal dose of SARS-CoV-2-SD614G via the nasal route, and partially protected if challenged with the SARS-CoV-2Delta variant. While dissemination of the challenge virus to the brain was completely inhibited, replication in the lung with consequent lung pathology was not entirely controlled. Thus, intramuscular immunization was clearly enhanced by trans-complementation of the VSV-vectored vaccines by the VSV glycoprotein and led to protection from COVID-19, although not achieving sterilizing immunity.
Collapse
|
15
|
Abstract
Mutations at spike protein L452 are recurrently observed in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOC), including omicron lineages. It remains elusive how amino acid substitutions at L452 are selected in VOC. Here, we characterized all 19 possible mutations at this site and revealed that five mutants expressing the amino acids Q, K, H, M, and R gained greater fusogenicity and pseudovirus infectivity, whereas other mutants failed to maintain steady-state expression levels and/or pseudovirus infectivity. Moreover, the five mutants showed decreased sensitivity toward neutralization by vaccine-induced antisera and conferred escape from T cell recognition. Contrary to expectations, sequence data retrieved from the Global Initiative on Sharing All Influenza Data (GISAID) revealed that the naturally occurring L452 mutations were limited to Q, M, and R, all of which can arise from a single nucleotide change. Collectively, these findings highlight that the codon base change mutational barrier is a prerequisite for amino acid substitutions at L452, in addition to the phenotypic advantages of viral fitness and decreased sensitivity to host immunity. IMPORTANCE In a span of less than 3 years since the declaration of the coronavirus pandemic, numerous SARS-CoV-2 variants of concern have emerged all around the globe, fueling a surge in the number of cases and deaths that caused severe strain on the health care system. A major concern is whether viral evolution eventually promotes greater fitness advantages, transmissibility, and immune escape. In this study, we addressed the differential effect of amino acid substitutions at a frequent mutation site, L452 of SARS-CoV-2 spike, on viral antigenic and immunological profiles and demonstrated how the virus evolves to select one amino acid over the others to ensure better viral infectivity and immune evasion. Identifying such virus mutation signatures could be crucial for the preparedness of future interventions to control COVID-19.
Collapse
|
16
|
Cuypers L, Dellicour S, Hong SL, Potter BI, Verhasselt B, Vereecke N, Lambrechts L, Durkin K, Bours V, Klamer S, Bayon-Vicente G, Vael C, Ariën KK, De Mendonca R, Soetens O, Michel C, Bearzatto B, Naesens R, Gras J, Vankeerberghen A, Matheeussen V, Martens G, Obbels D, Lemmens A, Van den Poel B, Van Even E, De Rauw K, Waumans L, Reynders M, Degosserie J, Maes P, André E, Baele G. Two Years of Genomic Surveillance in Belgium during the SARS-CoV-2 Pandemic to Attain Country-Wide Coverage and Monitor the Introduction and Spread of Emerging Variants. Viruses 2022; 14:2301. [PMID: 36298856 PMCID: PMC9612291 DOI: 10.3390/v14102301] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2022] [Revised: 10/14/2022] [Accepted: 10/17/2022] [Indexed: 11/21/2022] Open
Abstract
An adequate SARS-CoV-2 genomic surveillance strategy has proven to be essential for countries to obtain a thorough understanding of the variants and lineages being imported and successfully established within their borders. During 2020, genomic surveillance in Belgium was not structurally implemented but performed by individual research laboratories that had to acquire the necessary funds themselves to perform this important task. At the start of 2021, a nationwide genomic surveillance consortium was established in Belgium to markedly increase the country's genomic sequencing efforts (both in terms of intensity and representativeness), to perform quality control among participating laboratories, and to enable coordination and collaboration of research projects and publications. We here discuss the genomic surveillance efforts in Belgium before and after the establishment of its genomic sequencing consortium, provide an overview of the specifics of the consortium, and explore more details regarding the scientific studies that have been published as a result of the increased number of Belgian SARS-CoV-2 genomes that have become available.
Collapse
Affiliation(s)
- Lize Cuypers
- National Reference Centre for Respiratory Pathogens, Department of Laboratory Medicine, University Hospitals Leuven, 3000 Leuven, Belgium
| | - Simon Dellicour
- Spatial Epidemiology Lab (SpELL), Université Libre de Bruxelles, 1000 Brussels, Belgium
- Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, 3000 Leuven, Belgium
| | - Samuel L. Hong
- Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, 3000 Leuven, Belgium
| | - Barney I. Potter
- Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, 3000 Leuven, Belgium
| | - Bruno Verhasselt
- Department of Diagnostic Sciences, Ghent University Hospital, Ghent University, 9000 Ghent, Belgium
| | - Nick Vereecke
- PathoSense BV, Faculty of Veterinary Medicine, Ghent University, 9820 Merelbeke, Belgium
| | - Laurens Lambrechts
- HIV Cure Research Center, Department of Internal Medicine and Pediatrics, Ghent University Hospital, Ghent University, 9000 Ghent, Belgium
- BioBix, Department of Data Analysis and Mathematical Modelling, Faculty of Bioscience Engineering, Ghent University, 9000 Ghent, Belgium
| | - Keith Durkin
- Laboratory of Human Genetics, GIGA Research Institute, 4000 Liège, Belgium
| | - Vincent Bours
- Laboratory of Human Genetics, GIGA Research Institute, 4000 Liège, Belgium
- Department of Human Genetics, University Hospital of Liège, 4000 Liège, Belgium
| | - Sofieke Klamer
- Scientific Directorate of Epidemiology and Public Health, Sciensano, 1050 Brussels, Belgium
| | - Guillaume Bayon-Vicente
- Department of Proteomic and Microbiology, Research Institute for Biosciences, University of Mons, 7000 Mons, Belgium
| | - Carl Vael
- Clinical Laboratory, AZ Klina, 2930 Brasschaat, Belgium
| | - Kevin K. Ariën
- Virology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine Antwerp, 2000 Antwerp, Belgium
- Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, Department of Biomedical Sciences, University of Antwerp, 2000 Antwerp, Belgium
| | - Ricardo De Mendonca
- Department of Microbiology, CUB-Hôpital Erasme, Université Libre de Bruxelles, 1000 Brussels, Belgium
| | - Oriane Soetens
- Department of Microbiology and Infection Control, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, 1090 Brussels, Belgium
| | - Charlotte Michel
- Department of Microbiology, Laboratoire Hospitalier Universitaire de Bruxelles (LHUB-ULB), 1000 Brussels, Belgium
| | - Bertrand Bearzatto
- Center for Applied Molecular Technologies (CTMA), Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain (UCLouvain), 1000 Brussels, Belgium
| | - Reinout Naesens
- Department of Medical Microbiology, Ziekenhuis Netwerk Antwerpen, 2020 Antwerp, Belgium
| | - Jeremie Gras
- Institute of Pathology and Genetics (IPG), 6041 Gosselies, Belgium
| | - Anne Vankeerberghen
- Laboratory of Molecular Biology, Campus Aalst-Asse-Ninove, Onze-Lieve-Vrouwziekenhuis, 9300 Aalst, Belgium
| | - Veerle Matheeussen
- Laboratory of Medical Microbiology, Department of Microbiology, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, 2610 Wilrijk, Belgium
| | - Geert Martens
- Department of Laboratory Medicine, AZ Delta General Hospital, 8800 Roeselare, Belgium
| | - Dagmar Obbels
- Clinical Laboratory, Imelda Hospital, 2820 Bonheiden, Belgium
| | - Ann Lemmens
- Laboratory of Clinical Biology, AZ Sint-Maarten Hospital, 2800 Mechelen, Belgium
| | - Bea Van den Poel
- Clinical Laboratory, General Hospital Jan Portaels, 1800 Vilvoorde, Belgium
| | - Ellen Van Even
- Clinical Laboratory of Microbiology, HH Hospital Lier, 2500 Lier, Belgium
| | - Klara De Rauw
- Laboratory of Clinical Biology, AZ Sint Lucas Hospital, 9000 Ghent, Belgium
| | - Luc Waumans
- Clinical Laboratory, Jessa Hospital, 3500 Hasselt, Belgium
| | - Marijke Reynders
- Department of Laboratory Medicine, Medical Microbiology, AZ Sint-Jan Bruges-Ostend AV, 8000 Bruges, Belgium
| | - Jonathan Degosserie
- Federal Testing Platform COVID-19, Department of Laboratory Medicine, CHU UCL Namur, 5530 Yvoir, Belgium
- Next Generation Sequencing Platform, Molecular Diagnostic Center, CHU UCL Namur, 5530 Yvoir, Belgium
| | - Piet Maes
- Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, 3000 Leuven, Belgium
| | - Emmanuel André
- National Reference Centre for Respiratory Pathogens, Department of Laboratory Medicine, University Hospitals Leuven, 3000 Leuven, Belgium
- Federal Testing Platform COVID-19, Department of Laboratory Medicine, University Hospitals Leuven, 3000 Leuven, Belgium
- Laboratory of Clinical Microbiology, Department of Microbiology, Immunology and Transplantation, KU Leuven, 3000 Leuven, Belgium
| | - Guy Baele
- Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, 3000 Leuven, Belgium
| |
Collapse
|
17
|
Passive immunization against COVID-19 by anti-SARS-CoV-2 spike IgG in commercially available immunoglobulin preparations in severe antibody deficiency. THE JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY: IN PRACTICE 2022; 10:2452-2455.e3. [PMID: 35779780 PMCID: PMC9239915 DOI: 10.1016/j.jaip.2022.06.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/31/2022] [Revised: 06/10/2022] [Accepted: 06/13/2022] [Indexed: 11/21/2022]
|
18
|
Avetyan D, Hakobyan S, Nikoghosyan M, Ghukasyan L, Khachatryan G, Sirunyan T, Muradyan N, Zakharyan R, Chavushyan A, Hayrapetyan V, Hovhannisyan A, Mohamed Bakhash SA, Jerome KR, Roychoudhury P, Greninger AL, Niazyan L, Davidyants M, Melik-Andreasyan G, Sargsyan S, Nersisyan L, Arakelyan A. Molecular Analysis of SARS-CoV-2 Lineages in Armenia. Viruses 2022; 14:1074. [PMID: 35632815 PMCID: PMC9142918 DOI: 10.3390/v14051074] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2022] [Revised: 05/04/2022] [Accepted: 05/13/2022] [Indexed: 12/11/2022] Open
Abstract
The sequencing of SARS-CoV-2 provides essential information on viral evolution, transmission, and epidemiology. In this paper, we performed the whole-genome sequencing of SARS-CoV-2 using nanopore and Illumina sequencing to describe the circulation of the virus lineages in Armenia. The analysis of 145 full genomes identified six clades (19A, 20A, 20B, 20I, 21J, and 21K) and considerable intra-clade PANGO lineage diversity. Phylodynamic and transmission analysis allowed to attribute specific clades as well as infer their importation routes. Thus, the first two waves of positive case increase were caused by the 20B clade, the third peak caused by the 20I (Alpha), while the last two peaks were caused by the 21J (Delta) and 21K (Omicron) variants. The functional analyses of mutations in sequences largely affected epitopes associated with protective HLA loci and did not cause the loss of the signal in PCR tests targeting ORF1ab and N genes as confirmed by RT-PCR. We also compared the performance of nanopore and Illumina short-read sequencing and showed the utility of nanopore sequencing as an efficient and affordable alternative for large-scale molecular epidemiology research. Thus, our paper describes new data on the genomic diversity of SARS-CoV-2 variants in Armenia in the global context of the virus molecular genomic surveillance.
Collapse
Affiliation(s)
- Diana Avetyan
- Laboratory of Human Genomics, Institute of Molecular Biology NAS RA, Yerevan 0014, Armenia; (L.G.); (G.K.); (T.S.); (N.M.); (R.Z.); (A.C.); (V.H.)
- Institute of Biomedicine and Pharmacy, Russian-Armenian University, Yerevan 0051, Armenia; (M.N.); (A.H.)
| | - Siras Hakobyan
- Bioinformatics Group, Institute of Molecular Biology NAS RA, Yerevan 0014, Armenia;
- Armenian Bioinformatics Institute, Yerevan 0014, Armenia;
| | - Maria Nikoghosyan
- Institute of Biomedicine and Pharmacy, Russian-Armenian University, Yerevan 0051, Armenia; (M.N.); (A.H.)
- Bioinformatics Group, Institute of Molecular Biology NAS RA, Yerevan 0014, Armenia;
| | - Lilit Ghukasyan
- Laboratory of Human Genomics, Institute of Molecular Biology NAS RA, Yerevan 0014, Armenia; (L.G.); (G.K.); (T.S.); (N.M.); (R.Z.); (A.C.); (V.H.)
| | - Gisane Khachatryan
- Laboratory of Human Genomics, Institute of Molecular Biology NAS RA, Yerevan 0014, Armenia; (L.G.); (G.K.); (T.S.); (N.M.); (R.Z.); (A.C.); (V.H.)
- Institute of Biomedicine and Pharmacy, Russian-Armenian University, Yerevan 0051, Armenia; (M.N.); (A.H.)
| | - Tamara Sirunyan
- Laboratory of Human Genomics, Institute of Molecular Biology NAS RA, Yerevan 0014, Armenia; (L.G.); (G.K.); (T.S.); (N.M.); (R.Z.); (A.C.); (V.H.)
- Institute of Biomedicine and Pharmacy, Russian-Armenian University, Yerevan 0051, Armenia; (M.N.); (A.H.)
| | - Nelli Muradyan
- Laboratory of Human Genomics, Institute of Molecular Biology NAS RA, Yerevan 0014, Armenia; (L.G.); (G.K.); (T.S.); (N.M.); (R.Z.); (A.C.); (V.H.)
| | - Roksana Zakharyan
- Laboratory of Human Genomics, Institute of Molecular Biology NAS RA, Yerevan 0014, Armenia; (L.G.); (G.K.); (T.S.); (N.M.); (R.Z.); (A.C.); (V.H.)
- Institute of Biomedicine and Pharmacy, Russian-Armenian University, Yerevan 0051, Armenia; (M.N.); (A.H.)
| | - Andranik Chavushyan
- Laboratory of Human Genomics, Institute of Molecular Biology NAS RA, Yerevan 0014, Armenia; (L.G.); (G.K.); (T.S.); (N.M.); (R.Z.); (A.C.); (V.H.)
- Davidyants Laboratories, Yerevan 0054, Armenia
| | - Varduhi Hayrapetyan
- Laboratory of Human Genomics, Institute of Molecular Biology NAS RA, Yerevan 0014, Armenia; (L.G.); (G.K.); (T.S.); (N.M.); (R.Z.); (A.C.); (V.H.)
- Institute of Biomedicine and Pharmacy, Russian-Armenian University, Yerevan 0051, Armenia; (M.N.); (A.H.)
| | - Anahit Hovhannisyan
- Institute of Biomedicine and Pharmacy, Russian-Armenian University, Yerevan 0051, Armenia; (M.N.); (A.H.)
- Laboratory of Evolutionary Genomics, Institute of Molecular Biology NAS RA, Yerevan 0014, Armenia
| | - Shah A. Mohamed Bakhash
- Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98102, USA; (S.A.M.B.); (K.R.J.); (P.R.); (A.L.G.)
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
| | - Keith R. Jerome
- Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98102, USA; (S.A.M.B.); (K.R.J.); (P.R.); (A.L.G.)
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
| | - Pavitra Roychoudhury
- Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98102, USA; (S.A.M.B.); (K.R.J.); (P.R.); (A.L.G.)
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
| | - Alexander L. Greninger
- Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98102, USA; (S.A.M.B.); (K.R.J.); (P.R.); (A.L.G.)
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
| | - Lyudmila Niazyan
- NORK Infection Clinical Hospital, MoH RA, Yerevan 0047, Armenia; (L.N.); (M.D.)
| | - Mher Davidyants
- NORK Infection Clinical Hospital, MoH RA, Yerevan 0047, Armenia; (L.N.); (M.D.)
| | - Gayane Melik-Andreasyan
- National Center of Disease Control and Prevention, Ministry of Health RA, Yerevan 0025, Armenia; (G.M.-A.); (S.S.)
| | - Shushan Sargsyan
- National Center of Disease Control and Prevention, Ministry of Health RA, Yerevan 0025, Armenia; (G.M.-A.); (S.S.)
| | - Lilit Nersisyan
- Armenian Bioinformatics Institute, Yerevan 0014, Armenia;
- SciLifeLab, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 17177 Solna, Sweden
| | - Arsen Arakelyan
- Laboratory of Human Genomics, Institute of Molecular Biology NAS RA, Yerevan 0014, Armenia; (L.G.); (G.K.); (T.S.); (N.M.); (R.Z.); (A.C.); (V.H.)
- Institute of Biomedicine and Pharmacy, Russian-Armenian University, Yerevan 0051, Armenia; (M.N.); (A.H.)
- Bioinformatics Group, Institute of Molecular Biology NAS RA, Yerevan 0014, Armenia;
- Armenian Bioinformatics Institute, Yerevan 0014, Armenia;
| |
Collapse
|
19
|
Chouikha A, Lagare A, Ghedira K, Diallo A, Njouom R, Sankhe S, Derrar F, Victoir K, Dellagi K, Triki H, Diagne MM. SARS-CoV-2 Lineage A.27: New Data from African Countries and Dynamics in the Context of the COVID-19 Pandemic. Viruses 2022; 14:1007. [PMID: 35632749 PMCID: PMC9144831 DOI: 10.3390/v14051007] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2022] [Revised: 05/05/2022] [Accepted: 05/05/2022] [Indexed: 11/17/2022] Open
Abstract
SARS-CoV-2 is constantly evolving with lineages emerging and others eclipsing. Some lineages have an important epidemiological impact and are known as variants of interest (VOIs), variants under monitoring (VUMs) or variants of concern (VOCs). Lineage A.27 was first defined as a VUM since it holds mutations of concern. Here, we report additional lineage A.27 data and sequences from five African countries and describe the molecular characteristics, and the genetic history of this lineage worldwide. Based on the new sequences investigated, the most recent ancestor (tMRCA) of lineage A.27 was estimated to be from April 2020 from Niger. It then spread to Europe and other parts of the world with a peak observed between February and April 2021. The detection rate of A.27 then decreased with only a few cases reported during summer 2021. The phylogenetic analysis revealed many sub-lineages. Among them, one was defined by the substitution Q677H in the spike (S) gene, one was defined by the substitution D358N in the nucleoprotein (N) gene and one was defined by the substitution A2143V in the ORF1b gene. This work highlights the importance of molecular characterization and the timely submission of sequences to correctly describe the circulation of particular strains in order to be proactive in monitoring the pandemic.
Collapse
Affiliation(s)
- Anissa Chouikha
- Laboratory of Clinical Virology, WHO Reference Laboratory for Poliomyelitis and Measles in the Eastern Mediterranean Region, Pasteur Institute of Tunis, University Tunis El Manar (UTM), Tunis 1002, Tunisia;
- Reasearch Laboratory “Virus, Vectors and Hosts: One Health Approach and Technological Innovation for a Better Health”, LR20IPT02, Pasteur Institute, Tunis 1002, Tunisia
| | - Adamou Lagare
- Centre de Recherche Médicale et Sanitaire (CERMES), BP: 10887—634 Bd de la Nation, Niamey YN034, Niger;
| | - Kais Ghedira
- Laboratory of Bioinformatics, Biomathematics and Biostatistics (BIMS), Institut Pasteur de Tunis (IPT), 13, Place Pasteur BP 74, University of Tunis-El Manar, Tunis 1002, Tunisia;
| | - Amadou Diallo
- Institut Pasteur Dakar, 36 Avenue Pasteur, Dakar BP 220, Senegal; (A.D.); (S.S.); (M.M.D.)
| | - Richard Njouom
- Centre Pasteur of Cameroon, Centre Pasteur of Cameroon, 451 rue 2005, Yaoundé, Cameroon;
| | - Safietou Sankhe
- Institut Pasteur Dakar, 36 Avenue Pasteur, Dakar BP 220, Senegal; (A.D.); (S.S.); (M.M.D.)
| | - Fawzi Derrar
- Institut Pasteur d’Algérie, 01 Rue du Petite Staouéli, Dély-Brahim, Algiers 16047, Algeria;
| | - Kathleen Victoir
- Institut Pasteur, Direction Internationale, Pôle Coopération Scientifique, 25 Rue du Dr Roux, 75015 Paris, France;
| | - Koussay Dellagi
- Pasteur Network Association, Institut Pasteur 25 Rue du Dr Roux, 75015 Paris, France;
| | - Henda Triki
- Laboratory of Clinical Virology, WHO Reference Laboratory for Poliomyelitis and Measles in the Eastern Mediterranean Region, Pasteur Institute of Tunis, University Tunis El Manar (UTM), Tunis 1002, Tunisia;
- Reasearch Laboratory “Virus, Vectors and Hosts: One Health Approach and Technological Innovation for a Better Health”, LR20IPT02, Pasteur Institute, Tunis 1002, Tunisia
| | - Moussa Moise Diagne
- Institut Pasteur Dakar, 36 Avenue Pasteur, Dakar BP 220, Senegal; (A.D.); (S.S.); (M.M.D.)
| |
Collapse
|